ImmunityBio (IBRX) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $8.28B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Richard Gerald Adcock |
| IPO Date | 2015-07-28 | CAGR | 54.76% |
| Employees | 688 | Website | immunitybio.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.04% | Total Yield | 0.04% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $9.78B | P/E | -8.15 | Forward P/E | -62.45 | PEG | — |
| P/S | 327.65 | P/B | -51.96 | P/CF | -390.96 | P/FCF | -384.26 |
| Sales | $165.79M | Sales 1Y | 192.92% | Sales 3Y | 27905.41% | Sales 5Y | 25406.46% |
| EPS | $-0.97 | EPS 1Y | 110.14% | EPS 3Y | -20.2% | EPS 5Y | 23.24% |
| Sales QoQ | 15.91% | EPS QoQ | -64.52% | Sales QoQ Avg | 18.03% | EPS QoQ Avg | 196.27% |
| Gross Margin | 94.63% | Operating Margin | -151.88% | Profit Margin | -598.56% | ROCE | -45.63% |
| ROA | -158% | ROE | 135% | Altman Z Score | -0.3 | Piotroski Score | 4 |
| Current Ratio | 4.66 | Quick Ratio | 4.66 | Cash Ratio | 0.99 | Op. CF Ratio | -0.87 |
| Debt/Equity | -0.04 | Debt/Assets | 0.06 | Lt Debt/Equity | -0.03 | Lt Debt/Cap. | -0.03 |
| Intrst Cov. | -3.64 | Inventory Turnover | — | Asset Turnover | 0.26 | Receivables Turnover | — |
| Enterprise Value | $9.78B | P/E Ratio | -8.15 |
| Forward P/E | -62.45 | PEG Ratio | — |
| P/S Ratio | 327.65 | P/B Ratio | -51.96 |
| P/CF Ratio | -390.96 | P/FCF Ratio | -384.26 |
| EPS | $-0.97 | EPS Growth 1Y | 110.14% |
| EPS Growth 3Y | -20.2% | EPS Growth 5Y | 23.24% |
| Revenue Growth 1Y | 192.92% | Gross Margin | 0.95% |
| Operating Margin | -1.52% | Profit Margin | -5.99% |
| ROE | 1.35% | ROA | -1.58% |
| ROCE | -0.46% | Current Ratio | 4.66 |
| Quick Ratio | 4.66 | Cash Ratio | 0.99 |
| Debt/Equity | -0.04 | Interest Coverage | -3.64 |
| Altman Z Score | -0.3 | Piotroski Score | 4 |
ImmunityBio (IBRX) valuation & financials
ImmunityBio (IBRX) has a market capitalization of $8.28B and trades at a price-to-earnings ratio of -8.2. It operates in the Healthcare sector (Biotechnology).
ImmunityBio's revenue grew +192.9% over the last year.
ImmunityBio's next earnings report is scheduled for November 3, 2026 before market open; analysts estimate EPS of $-0.08. Check the earnings calendar to see all companies reporting this week.
ImmunityBio (IBRX) — frequently asked questions
When does ImmunityBio (IBRX) report earnings next?
ImmunityBio is expected to report earnings on November 3, 2026 before market open. Analysts estimate EPS of $-0.08.
What is ImmunityBio's market cap?
ImmunityBio (IBRX) has a market capitalization of $8.28B.
What is IBRX's P/E ratio?
ImmunityBio trades at a price-to-earnings ratio of -8.2, with trailing twelve-month EPS of $-0.97.
How fast is ImmunityBio growing?
ImmunityBio's revenue grew +192.9% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)